Reported Sunday, Alnylam Reported Interim Phase 1 Results For Nucresiran (ALN-TTRsc04), Demonstrating Rapid And Sustained TTR Reduction Lasting Six Months After A Single Dose
Reported Sunday, Alnylam Reported Interim Phase 1 Results For Nucresiran (ALN-TTRsc04), Demonstrating Rapid And Sustained TTR Reduction Lasting Six Months After A Single Dose
週日報道，Alnylam報告了Nucresiran（ALN-TTRsc04）的中期1期結果，展示了單劑後持續六個月的快速和持久的TTR減少。
- Single Dose of Nucresiran 300mg or Higher Led to Rapid Knockdown of Mean TTR Levels of Greater than 90% by Day 15 that was Sustained at Six Months
- At These Doses, Peak Reduction of Mean TTR Levels of Greater than 96% were Achieved by Day 29 −
- Data Support Potential for Biannual or Annual Subcutaneous Dosing, Representing a New Paradigm in the Treatment of ATTR Amyloidosis −
- Encouraging Safety and Tolerability Observed −
- Alnylam Continues to Expect to Share Phase 3 Development Plans in Q1 2025 –
資訊熱榜
更新時間